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DNA damageAbstract Clozapine is an atypical antipsychotic drug selectively effective in the treatment of refrac-
tory schizophrenia. However, myocarditis, as a serious cardiotoxic effect, has in several case reports
been associated with clozapine therapy. An increase in the free radical production and ischemia,
probably induced by clozapine-induced release of catecholamines, have been hypothesized to trigger
an inﬂammatory response that leads to the clinically observed cardiomyopathy and sudden death
even in young patients. The aim of this work is to study the role of oxidative stress in clozapine-
induced myocarditis and myocardial DNA damage in a rat model.
Methods: Male Wistar rats, age 6 weeks, were administered 5, 10 or 25 mg/kg clozapine daily for
21 days; saline-treated rats served as the control. Heart sections were stained with hematoxylin and
eosin for histopathological examination. Plasma CK-MB, LDH and TNF-a concentrations were
determined. Myocardial oxidative stress (MDA and NO), antioxidant (GSH and GSH-Px) param-
eters, and the marker of oxidative DNA damage (8-OHdG) were determined.
Results: Clozapine treatment resulted in signiﬁcant dose-related increases in myocardial inﬂamma-
tion with increased plasma TNF-a, CK-MB and LDH levels. Myocardial MDA, NO and serum
and cardiac 8-OHdG levels increased while GSH level and GSH-Px activity decreased with the
highest signiﬁcance seen with the largest tested dose (25 mg/kg) of clozapine.
Conclusions: Clozapine, in relatively large doses induced myocarditis consistently with increased
myocardial oxidative stress, DNA damage and inﬂammatory cytokines in a rat model.
ª 2014 The International Association of Law and Forensic Sciences (IALFS). Production and hosting by
Elsevier B.V. All rights reserved.iobis-2-
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76 B.A. Abdel-Wahab et al.1. Introduction
Clozapine, a tricyclic dibenzodiazepine, belongs to the class of
second-generation antipsychotics that are often called atypical
antipsychotics. It has a strong afﬁnity for D4-dopami-nergic
receptors1 and potent serotonergic, noradrenergic, histamine2,3
and cholinergic M2 receptor blocking activity.4 It differs from
traditional antipsychotic drugs in that it has a relatively weak
D2-receptor activity.1 The main advantage of clozapine is that
it rarely causes extrapyramidal symptoms, which are common
with conventional antipsychotics, in addition to its effective-
ness in treating resistant schizophrenia.5
However, some toxic effects of clozapine caused the Food
and Drug Administration (FDA) to restrict its use, requiring
close monitoring conditions and reserving the medication for
treatment-resistant schizophrenia unresponsive to conven-
tional antipsychotics. Among these adverse effects are agran-
ulocytosis that occurs in about 1% of patients,5 venous
thromboembolism6 and seizures.7 A commonly reported
and serious adverse effect of clozapine is its potential to
induce cardiotoxicity and myocarditis. Myocarditis has been
reported in many clinical case reports in young schizo-
phrenic patients on clozapine therapy, without previous car-
diovascular diseases.8 Additionally, health professionals are
being warned of potentially fatal myocarditis, cardiomyopa-
thy, pericarditis, heart failure and eventually death associ-
ated with clozapine.9
The exact pathogenesis and incidence of clozapine-induced
myocarditis is not clearly understood up till now. Previous
studies have shown the role of increased catecholamines. Clo-
zapine treatment has been associated with increased plasma
levels of the catecholamines, norepinephrine and epineph-
rine.10 In addition, hyper-catecholaminergic states can cause
or signiﬁcantly exacerbate myocarditis in animals and
patients.11 While, the increase in cardiac catecholamines by
clozapine cannot be considered the sole cause, involvement
of inﬂammatory cytokines cannot be neglected. Clozapine-
induced myocarditis has been associated with an increased
release of inﬂammatory cytokines, including interleukins and
tumor necrosis factor alpha (TNF-a).12
Previous studies have postulated an increase in the level
of reactive oxygen species (ROS) in the myocardium during
the development of myocarditis and heart failure in experi-
mental animals and in human patients.13 Myocardial ische-
mia, which may result from a clozapine-induced increase
in catecholamine release, can lead to cell injury with the
release of ROS.14 Cell injury in the ischemic area also causes
inﬁltration of neutrophils, which produce oxidants and cyto-
kines. Certain cytokines such as tumor necrosis factor-a
(TNF-a) trigger the mitochondrial release of ROS.15 In
addition, an increase in ROS have been detected in various
animal models of heart failure. An increase in oxidative
stress due to increased production of ROS, a relative deﬁcit
in the endogenous antioxidant reservoir, or both can cause
myocarditis, contractile dysfunction and cardiomyopa-
thy.16,17 Moreover, oxygen free radical damage has been
implicated as a precipitating event in ischemia-, overload-,
or drug-induced heart failure.18
Hence, the purpose of this study was to ﬁnd an answer for
this question: Does clozapine induce myocarditis via increasing
myocardial oxidative stress and DNA damage in rats?2. Materials and methods
2.1. Chemicals
Clozapine (8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo
[be] [1,4] diazepine) (Sigma Aldrich, St. Louis, MO) was dis-
solved in 0.1 M HCl and pH balanced in phosphate buffered
saline (PBS) (Sigma Aldrich, St. Louis, MO). Solution was
administered intraperitoneally (i.p.) daily in 0.1 ml doses.
Thiobarbituric acid, reduced glutathione (GSH), Griss
reagent, Ellman’s reagent [5,5-dithiobis (2-nitrobenzoic acid),
DTNB] and bovine serum albumin (BSA) were purchased
from Sigma (Germany). Cayman’s 8-hydroxy-2-deoxy guano-
sine (8-OHdG) assay kit was purchased from Cayman’s Chem-
ical Co. (USA). All the reagents used in this study were of
analytical grade.
2.2. Animals
Male Wistar rats with 160–180 g body weight from the animal
house of the King Saud University, Riyadh, Saudi Arabia were
used in this study. Animals were housed in groups of 5 rats in
standard clear polycarbonate cages with food and water avail-
able ad libitum. Animals were kept on a 12-h light–dark sche-
dule (6:00 am–6:00 pm), and all experimental testing was
conducted during the light phase from 9:00 am to 12:00 pm.
All experiments were carried out in accordance with the
National Institutes of Health guide for the care and use of lab-
oratory animals (NIH Publications No. 8023, revised 1978).
The experimental protocol was approved by the Institutional
Animal Use and Care Committee. All efforts were made to
minimize animal suffering and to reduce the number of ani-
mals used.
2.3. Experimental protocol
The animals were divided into four groups, ten rats for each.
Clozapine was administered in doses of 10, 15 and 25 mg/kg/
day i.p. for 21 days in three groups. The fourth group was used
as the control and was treated with physiological saline.Moder-
ate to high doses of clozapine were used based on previous
reports.11 Mortality and animal weights were recorded during
the course of treatment as an index for clozapine toxicity. On
the last day of clozapine or saline administration, animals were
anesthetized with 45 mg/kg ketamine and 5 mg/kg xylazine i.p.
(Sigma Aldrich, St. Louis, MO), blood was drawn by cardiac
puncture. Blood samples were centrifuged at 1300 g at 25 C
for 15 min. and serum was obtained. Animals were sacriﬁced
by decapitation and hearts were excised, washed with ice-cold
saline, blotted with a piece of ﬁlter paper and divided longitudi-
nally into two halves. One-half of each heart was homogenized
using a Bio-Gen pro 200 homogenizer (Pro Scientiﬁc, Oxford,
UK) in phosphate buffer (pH 7). The homogenates were centri-
fuged at 1300g at 4 C for 15 min. The supernatant of the
homogenate and serum were used for biochemical assays.
2.4. Histopathology
Ventricles of the second half of each heart were ﬁxed in a 10%
neutral formalin solution, then embedded in parafﬁn,
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and eosin (H/E), and examined by light microscopy. The ven-
tricle specimens were evaluated for typical histopathological
features associated with clozapine-induced cardiotoxicity
(including inﬂammation, myocyte vacuolar degradation,
necrosis of myoﬁbers, and interstitial ﬁbrosis). Histological
evidence of myocarditis was classiﬁed in terms of the degree
of cellular inﬁltration and graded on a 5-point scale ranging
from 0 to 4+.
19 A zero score indicated no or questionable
presence of lesions in each category. A 1+ score described a
limited focal distribution of myocardial lesions. A 2+ to
3+ score described intermediate severity with multiple lesions,
whereas a 4+ score described the presence of coalescent and
extensive lesions over the entire examined heart tissue.
2.5. Biochemical assays
2.5.1. Determination of serum creatine kinase (CK-MB)
activity
Creatine kinase activity was estimated in serum by commer-
cially available CK-MB assay kit (Bioassay Systems, USA)
adopting the method of Bishop.20 This assay is based on the
conversion of creatine phosphate and ADP by creatine kinase
to creatine and ATP. The ATP and glucose are then converted
to ADP and glucose-6-phosphate by hexokinase (HK). Glu-
cose-6-phosphate dehydrogenase (G6PD) then oxidizes glu-
cose-6-phosphate and reduces the nicotinamide adenine dinu-
cleotide (NAD) to NADH. The rate of NADH formation,
measured at 340 nm, is, therefore, directly proportional to cre-
atine kinase activity.
2.5.2. Determination of serum lactate dehydrogenase (LDH)
activity
Lactate dehydrogenase activity was estimated in serum by
commercially available LDH kit (Linear Chemicals, S.L.,
UK) according to the method of Whitaker.21 Using this
method, lactate dehydrogenase (LDH) catalyzes the reduction
of pyruvate to lactate in the presence of reduced nicotinamide
adenine dinucleotide (NADH) at pH 7.5. The reaction is mon-
itored kinetically at 340 nm using an UV–Visible spectropho-
tometer (Shimadzu, Japan) by the rate of decrease in
absorbance resulting from the oxidation of NADH to
NAD+ which is proportional to the activity of LDH present
in the sample.
2.5.3. Determination of tumor necrosis factor alpha (TNF-a)
The quantitative measurement of TNF-a in the cardiac
homogenate was performed using commercially available
ELISA kits (Quantikine ELISA kit; R&D Systems, Minneap-
olis, USA) according to manufacturer’s instructions.
2.5.4. Determination of lipid peroxidation
The quantitative measurement of lipid peroxidation in the car-
diac homogenate was performed according to the method pre-
viously described by Ohkawa.22 The amount of
malondialdehyde (MDA)–a measure of lipid peroxidation–
was measured by reaction with thiobarbituric acid at 532 nm
using an Optima SP 3000 plus spectrophotometer (Indogama,
Japan).2.5.5. Determination of nitric oxide
The level of NO was measured in the cardiac homogenate
by assaying nitrite, one of the stable products of NO oxida-
tion. The method was carried out as described by Green.23
Nitrite concentration was measured spectrophotometrically
using the Griss reagent [1% sulfanilamide in 5% phosphoric
acid (sulfanilamide solution) and 0.1% N-1-naphthylethylen-
edi-amine dihydrochloride in double distilled water]. A stan-
dard curve was plotted. Nitrite concentrations in samples
were expressed as micromoles per gram protein (lmol/g
protein).
2.5.6. Determination of GSH level and GSH-Px activity
For determination of intracellular GSH, an equal volume of
perchloric acid (1 mol/l) was added to a part of cardiac
homogenate and mixed by vortexing. The mixture was allowed
to stand for 5 min at room temperature. After centrifugation
for 5 min, the supernatant was collected. The GSH content
of the neutralized supernatant was assayed using Ellman’s
reagent [5,5-dithiobis-2-nitrobenzoic acid (DTNB solution)]
according to the method of Grifﬁth.24
GSH-Px activity was measured by the method of Paglia.25-
The enzymatic reaction, which contained b-nicotinamide ade-
nine dinucleotide phosphate (NADPH), GSH, glutathione
reductase and a sample or a standard, was initiated by the
addition of hydrogen peroxide. The change in absorbance
was measured spectrophotometrically. A standard curve was
plotted for each assay.
2.5.7. Determination of 8-OHdG levels
8-OHdG is produced by the oxidative damage of DNA by
reactive oxygen and nitrogen species and serves as an estab-
lished marker of oxidative stress. Cayman’s 8-hydroxy-20-
deoxy guanosine assay kit purchased from Cayman’s Chemical
Co. (USA) was used. It is a competitive assay that can be used
for the quantiﬁcation of 8-OHdG in serum and tissue homog-
enate. It recognizes both free and DNA-incorporated 8-
OHdG. This assay depends on the competition between 8-
OHdG and 8-OHdG-acetylcholinesterase (ache) conjugate
(8-OHdG tracer) for a limited amount of 8-OHdG monoclonal
antibody. All procedures were carried out in accordance with
manufacturer’s instructions.
2.5.8. Estimation of total protein
Total protein in hippocampal homogenate was estimated using
the method of Lowry.26 The absorption was read spectropho-
tometrically at 750 nm. Bovine serum albumin was used as
standard.
2.6. Statistical analysis
The Instat version 2.0 (graph pad Prism 5, ISI Software, Phil-
adelphia, PA, USA, 1993) computer program was used to
compute statistical data. All experimental results are expressed
as the mean ± SEM. Comparisons between experimental and
control groups were performed by one-way analysis of vari-
ance (ANOVA) followed by Bonferroni’s test for post hoc
comparison when appropriate. A value of p< 0.05 was con-
sidered signiﬁcant.
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3.1. Clozapine-induced myocarditis
Table 1 shows that rats treated with clozapine (25 mg/kg)
had a higher increase in mortality (20%) and an increase
in body weight (9 g ± 1.26) at the end of the experiments.
Rats treated with clozapine of 10 and 15 mg/kg showed an
increase in body weight 2.6 g ± 0.32 and 4 g ± 0.43, respec-
tively. No mortality was observed in these two groups.
Heart tissues revealed histological ﬁndings within normal
limits in the control group (Figure 1A). In clozapine-treated
groups, histological sections revealed interstitial edema, per-
inuclear vacuolation, evident focal sub-endocardial ﬁbrosis
and disorganization and degradation of the myocardium.
Myocardial inﬂammation increased with increasing clozapine
dose with the highest scores at dose 25 mg/kg/d (Figures
1B–D) and was signiﬁcantly increased relative to controls
on day 21 of clozapine treatment for all doses (Table 1).
Inﬂammatory lesions were found in both the left and right
ventricles, primarily in the myocardium below the endocar-
dium of the left ventricle, in the posterior papillary muscle
of the left ventricle and the septum, consistent with
myocarditis.
3.2. Effect on Serum CK-MB and LDH activities
Results from the measurement of serum CK-MB and LDH
showed signiﬁcant changes in its levels among the tested
groups [F(3, 39) = 8.538, p= 0.0002] and [F(3, 39) = 6.398,
p= 0.0014], respectively. Serum CK-MB signiﬁcantly
increased with the dose of 15 mg/kg/d (p< 0.05) and with
the dose of 25 mg/kg/d (p< 0.01) compared with the control
group (Figure 2). In addition, the serum LDH level signiﬁ-
cantly increased (p< 0.05) with the dose of 10 mg/kg/d and
(p< 0.01) with the doses of 15 and 25 mg/kg/d of clozapine
(Figure 3).
3.3. Effect on cardiac TNF-a level
Results revealed signiﬁcant changes in cardiac levels of
TNF-a after treatment with clozapine [F(3, 39) = 6.511,
p= 0.0012]. Clozapine treatment signiﬁcantly increased the
TNF-a level (p < 0.05) with the dose of 15 mg/kg/d and
(p< 0.01) with the dose of 25 mg/kg/d relative to the con-
trol group (Figure 4).Table 1 Histopathological scoring and percent of animals showed m
and 25 mg/kg/d on day 21.
Treatment (mg/kg/d) Initial body weight (g) Final body weight
Control 165 ± 2.34 168 ± 2.78
Clozapine (10) 175 ± 1.55 177.6 ± 0.32
Clozapine (15) 170 ± 2.62 174 ± 2.19
Clozapine (25) 165 ± 1.93 174 ± 0.62
Histological scores of hearts ranged from 0 to 4 + for myocarditis.
Results represent mean ± SEM (n= 10).
a p< 0.05 vs. control.
b p< 0.01 vs. control.
c p< 0.001 vs. control.3.4. Effect on cardiac anti-oxidants
Results obtained from the effects of clozapine on cardiac levels
of MDA, NO, GSH and GSH-Px activity are shown in Table 2.
Results showed that clozapine treatment signiﬁcantly affected
myocardial lipid peroxidation and cardiac levels of MDA [F(3,
39) = 7.158, p= 0.0007]. Post hoc analysis indicated that clo-
zapine treatment signiﬁcantly increased cardiac MDA levels
(p< 0.05) with the dose of 15 mg/kg/d and (p< 0.01) with
the dose of 25 mg/kg/d relative to the control group level. In
addition, regarding the myocardial NO level, there was a sig-
niﬁcant difference between the treated groups [F(3, 39) =
7.374, p= 0.0006]. Clozapine treatment signiﬁcantly increased
cardiac NO levels (p< 0.05) with the dose of 15 mg/kg/d and
(p< 0.01) with the dose of 25 mg/kg/d relative to the control
group level.
Moreover, clozapine treatment signiﬁcantly decreased myo-
cardial GSH levels [F(3, 39) = 3.512, p= 0.0248]. The effect
was statistically signiﬁcant at the dose of 25 mg/kg/d relative
to the control level. Furthermore, clozapine treatment signiﬁ-
cantly attenuated the GSH-Px activity [F(3, 39)=4.586,
p= 0.0081], the effect that was signiﬁcant with the dose of
15 mg/kg/d and (p< 0.01) with the dose of 25 mg/kg/d rela-
tive to the control group level.
3.5. Effect on serum and cardiac 8-OHdG levels
8-hydroxy-20-deoxyguanosine (8-OHdG) is a product of oxida-
tive damaged DNA formed by hydroxy radical and singlet oxy-
gen. Results from the measurement of 8-OHdG levels revealed
signiﬁcant changes among clozapine-treated groups [F(3, 39)
=8.850, p= 0.0002] and [F(3, 39)=6.512, p= 0.0012] in both
serum and cardiac tissues, respectively (Figure 5A).
After 21 days of clozapine treatment, the serum levels of 8-
OHdG signiﬁcantly increased with the doses of 15 and 25 mg/
kg/d at signiﬁcant levels p< 0.05 and p< 0.01, respectively.
The level of 8-OHdG in hearts of the tested animals signiﬁ-
cantly increased with clozapine dose of 10 mg/kg/d. The
increase was at the signiﬁcant level (p< 0.01) with the doses
of 15 and 25 mg/kg/d compared with the control group levels
(Figure 5B).
4. Discussion
In this study, it was investigated whether clozapine induces
myocarditis and myocardial oxidative stress and DNA damageyocarditis in control and clozapine-treated rats in doses of 10, 15,
(g) Change body weight (g) % Mortality Myocarditis
3.0 ± 1.44 0.00 0.00 ± 0.00
2.60 ± 0.32 0.00 0.33 ± 0.07a
4.00 ± 0.43a 0.00 0.67 ± 0.12b
9.00 ± 1.26b 20.00 0.86 ± 0.12c
Figure 2 Serum levels of creatinine phosphokinase isoenzyme
(CK-MB) of rats treated with clozapine in doses of 10, 15 (n= 10)
and 25 (n= 8) mg/kg/d, i.p. for 21 days. Results in each group
represent mean ± SEM. p< 0.05 vs. control. p< 0.01 vs.
control.
Figure 3 Serum levels of lactate dehydrogenase (LDH) of rats
treated with clozapine in doses of 10, 15 (n= 10) and 25 (n= 8)
mg/kg/d, i.p. for 21 days. Results in each group represent
mean ± SEM. p< 0.05 vs. control. p< 0.01 vs. control.
Figure 1 Representative H&E-stained sections (40) of the left ventricle from clozapine-treated and control rats. (A) There is no
myocardial inﬂammation in control rats (score 0). (B) There are inﬂammatory lesions in the myocardium after administration of 10 mg/
kg/d clozapine for 21 days (score 2). (C) There are larger inﬂammatory lesions in the myocardium after administration of 15 mg/kg/d
clozapine for 21 days (score 3). (D) There are extensive inﬂammatory lesions in the myocardium after administration of 25 mg/kg/d
clozapine for 21 days (score 4).
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induces myocarditis, myocardial oxidative stress and increases
DNA damage.
The ﬁrst ﬁnding was that clozapine-induced cardiotoxicity
was manifested by histopathological changes in the heart in
the form of inﬂammatory lesions, interstitial edema, perinu-
clear vacuolation and focal subendocardial ﬁbrosis, which
were dose-related and found in both the left and right ventri-
cles, mainly in the myocardium, consistent with myocarditis.
This ﬁnding is similar and related to histopathological changesthat have been shown in previous reports.27 This cardiotoxic
effect was conﬁrmed by elevation in the activities of serum lac-
tate dehydrogenase (LDH) and creatinine kinase (CK-MB).
Elevation of serum LDH and CK-MB enzymes are considered
important markers of early and late cardiac injury.
Additional evidence comes from Killian,28 who argued that
clozapine-induced myocarditis possibly results from a type-I
IgE-mediated acute hypersensitivity reaction. In addition, evi-
dence of a possible linkage between myocarditis induced by
clozapine and eosinophilic myocardial inﬁltrates was previ-
ously reported.29
Figure 4 Cardiac levels of tumor necrosis factor alpha (TNF-a)
of rats treated with clozapine in doses of 10, 15 (n= 10) and 25
(n= 8) mg/kg/d, i.p. for 21 days. Results in each group represent
mean ± SEM. p< 0.05 vs. control. p< 0.01 vs. control.
Figure 5 Effects of clozapine in doses 10, 15 (n= 10) and 25
(n= 8) mg/kg/d, i.p. for 21 days on (A) serum (B) cardiac 8-
hydroxy-2-deoxyguanosine (8-OHdG) levels in rats. Results in
each group represent mean ± SEM. *p< 0.05 vs. control.
**p< 0.01 vs. control.
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that clozapine-induced myocarditis involves proinﬂammatory
cytokine release, and increased level of proinﬂammatory cyto-
kines such as TNF-a level.30 Although previous studies
showed that atypical antipsychotic drugs including clozapine
showed the ability to decrease the levels of proinﬂammatory
cytokines in psychotic patients in therapeutic doses,31 these
ﬁndings showed that clozapine in large doses increases TNF-
a level one of the proinﬂammatory cytokines in a dose-related
pattern. These results are inconsistent with and support the
work of others.32
Previous studies have found that clozapine induces a rise in
plasma catecholamines that correlates with the degree of myo-
cardial inﬂammation.33 Thus, the imbalance in the autonomic
system with decreased parasympathetic tone and increased
adrenergic drive might explain the electrophysiological effects
of the drug, mainly tachycardia at rest. Persistent inappropri-
ate tachycardia has been demonstrated to induce an impair-
ment of left ventricular function both in animal models and
in humans.34
These results showed that clozapine-induced cardiotoxicity
was associated with marked elevation of myocardial levels of
the lipid peroxidation product (MDA), with reduction of
GSH content and activity of the antioxidant enzyme GSH-
Px. Therefore, these results give evidence for the concept that
increased oxidative stress and weakness of antioxidant
defenses play an important role in clozapine-induced
myocarditis.35Table 2 Effect of clozapine in doses 10, 15 and 25 mg/kg/day
intracellular reduced glutathione (GSH) levels and glutathione perox
Treatment (mg/kg/d) MDA (lmol/g protein) Nitrite (lmol
Control (n= 10) 315.62 ± 15.34 3.33 ± 1.14
Clozapine (10) (n= 10) 332.26 ± 17.25 3.64 ± 2.38
Clozapine (15) (n= 10) 387.63 ± 13.26a 10.34 ± 1.23a
Clozapine (25) (n= 8) 412.52 ± 21.32b 11.24 ± 1.12b
Results in each group represent mean ± SEM.
a p< 0.05 vs. control rats.
b p< 0.01 vs. control rats.Increasing oxidative stress is associated with an impaired
antioxidant defense status, which initiates a cascade of reac-
tions responsible for clozapine-induced cardiotoxicity.36 Clo-
zapine undergoes bioactivation in the myocardial tissues
converting into a chemically reactive nitronium ion metabolite.
This reactive metabolite stimulates cellular injury, lipid perox-
idation and free radical formation.37 This nitronium ion binds
with proteins in the myocardium leading to the formation of
antigenic complex that stimulates immune response and mac-
rophages,38 which leads to the release of proinﬂammatoryfor 21 days, on myocardial malondialdehyde (MDA), nitrite,
idase (GSH-Px) activity in rats.
/g protein) GSH (nmol/g protein) GSH-Px (IU/g protein)
33.46 ± 3.52 25.45 ± 3.24
30.45 ± 3.33 18.34 ± 2.48
23.46 ± 3.25 14.67 ± 2.66a
19.85 ± 3.23b 12.45 ± 2.13 b
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and myocarditis and generates further free radicals.
Catecholamines decrease myocardial oxygen perfusion
through coronary vasoconstriction.39 In addition, these results
showed that clozapine increases the cardiac level of nitrites, a
stable product and indirect marker of NO, which is consistent
with similar results that have demonstrated an increase in car-
diac NO levels following exposure to clozapine’s effect or its
metabolite N-desmethylclozapine.40 The contribution of NO
to clozapine-induced cardiac damage is suggested by evidence
demonstrating clozapine-mediated induction of nitric oxide
synthase (iNOS) expression.41
These results conﬁrmed the increase in free radical forma-
tion and the decrease in antioxidant defenses on long-term
treatment with clozapine. One limitation of this study is that
the experiment has thus far been conducted only on rats. It
would be valuable to conduct a clinical study for comparison
with these ﬁndings. The aim would be to measure the same
markers of cardiotoxicity in healthy volunteers and in schizo-
phrenic patients, without a history of preexisting cardiovascu-
lar disease.
The results of this study do not only conﬁrm an association
between clozapine treatment and the formation of myocarditis
lesions, but also showed the involvement of increased myocar-
dial oxidative stress and DNA damage in clozapine-induced
myocarditis.
5. Conclusion and recommendations
In conclusion, clozapine, particularly in moderate to high
doses, can produce a serious and potentially lethal cardio-
toxicity in the form of myocarditis and myocardial injury
in rats. The pathogenesis of this toxic reaction according
to the results of this study is attributed to increased myocar-
dial oxidative stress, inﬂammatory cytokines and oxidative
DNA damage with attenuation in antioxidant defenses. Clin-
ically, patients should be informed of symptoms of cardio-
toxicity. It is important to note that a high degree of
clinical suspicion is maintained through the duration of clo-
zapine therapy with a low threshold for referral to a
cardiologist.
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